RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer.

Amanda J Compadre Lillian N van Biljon Mark C Valentine Alba Llop-Guevara Emily Graham Bisiayo Fashemi Andrea Herencia-Ropero Emilee N Kotnik Isaac Cooper Shariska P Harrington Lindsay M Kuroki Carolyn K McCourt Andrea R Hagemann Premal H Thaker David G Mutch Matthew A Powell Lulu Sun Nima Mosammaparast Violeta Serra Peinan Zhao Elena Lomonosova Dineo Khabele Mary M Mullen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

RAD51 foci are a robust marker of platinum chemotherapy response and survival in ovarian cancer. The utility of RAD51 foci as a predictive biomarker for HGSOC should be tested in clinical trials.

Keyphrases

dna damage
dna repair
clinical trial
locally advanced
oxidative stress
randomized controlled trial
free survival
rectal cancer
phase ii